Detection of Hepatocellular Carcinoma and Liver Metastases with BR14: A Multicenter Phase IIA Study

Ultrasound in Medicine and Biology

Volumn 38, Issue 3, 2012, Pages 377-382

  Hohmann, Joachim ^e   Müller, Anja ^b   Skrok, Jan ^a   Wolf, Karl Jürgen ^a   Martegani, Alberto ^c   Dietrich, Christoph F ^d   Albrecht, Thomas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^c VALDUCE HOSPITAL   (Italy)

^d CARITAS KRANKENHAUS   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

BR14; Contrast agent; Detection; Hepatocellular carcinoma; Liver metastases; Phase IIa study; Ultrasonography

Indexed keywords

BR14; CONTRAST AGENT; HEPATOCELLULAR CARCINOMA; LIVER METASTASES; PHASE IIA STUDY;

ERROR DETECTION; IMAGE QUALITY; ULTRASONOGRAPHY;

PATHOLOGY;

BR 14; ECHO CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ERROR; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ECHOGRAPHY; FEMALE; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MICROBUBBLE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SIDE EFFECT; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROCARBONS; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84856563206     PISSN: 03015629     EISSN: 1879291X     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2011.11.018     Document Type: Article

References (14)

1. Albrecht T., Blomley M., Bolondi L., Claudon M., Correas J.M., Cosgrove D., Greiner L., Jager K., Jong N.D., Leen E., Lencioni R., Lindsell D., Martegani A., Solbiati L., Thorelius L., Tranquart F., Weskott H.P., Whittingham T. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004, 25:249-256.
2. Albrecht T., Blomley M.J.K., Burns P.N., Wilson S.R., Harvey C.J., Leen E., Claudon M., Calliada F., Correas J.M., LaFortune M., Campani R., Hoffmann C.W., Cosgrove D.O., LeFevre F. Improved detection of hepatic metastases with pulse inversion ultrasonography during the liver-specific phase of SHU 508A (Levovist): A multicenter study. Radiology 2002, in press.
3. Basilico R., Blomley M.J., Cosgrove D.O., Liull J.B., Broillet A., Bauer A., Bonomo L. The first phase I study of a novel ultrasound contrast agent (BR14): Assessment of safety and efficacy in liver and kidneys. Acad Radiol 2002, 9(suppl 2):S380-381.
4. Claudon M., Cosgrove D., Albrecht T., Bolondi L., Bosio M., Calliada F., Correas J.M., Darge K., Dietrich C., D'Onofrio M., Evans D.H., Filice C., Greiner L., Jager K., Jong N., Leen E., Lencioni R., Lindsell D., Martegani A., Meairs S., Nolsoe C., Piscaglia F., Ricci P., Seidel G., Skjoldbye B., Solbiati L., Thorelius L., Tranquart F., Weskott H.P., Whittingham T. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS): update 2008. Ultraschall Med 2008, 29:28-44.
5. Couinaud C. Le foie. Etudes anatomiques et chirurgicales 1957, Masson, Paris.
6. Dietrich C.F., Kratzer W., Strobe D., Danse E., Fessl R., Bunk A., Vossas U., Hauenstein K., Koch W., Blank W., Oudkerk M., Hahn D., Greis C. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006, 12:1699-1705.
7. Hohmann J., Albrecht T., Hoffmann C.W., Wolf K.J. Ultrasonographic detection of focal liver lesions: Increased sensitivity and specificity with microbubble contrast agents. Eur J Radiol 2003, 46:147-159.
8. Hohmann J., Skrok J., Puls R., Albrecht T. Rofo 2003, 175:835-843.
9. Oldenburg A., Hohmann J., Foert E., Skrok J., Hoffmann C.W., Frericks B., Wolf K.J., Albrecht T. Detection of hepatic metastases with low MI real-time contrast-enhanced sonography and SonoVue. Ultraschall Med 2005, 26:277-284.
10. Oudkerk M., Torres C.G., Song B., Konig M., Grimm J., Fernandez-Cuadrado J., Op de Beeck B., Marquardt M., van Dijk P., de Groot J.C. Characterization of liver lesions with mangofodipir trisodium enhanced MR imaging: Multicenter study comparing MR and dual-phase spiral-CT. Radiology 2002, 223:517-524.
11. Quaia E., Calliada F., Bertolotto M., Rossi S., Garioni L., Rosa L., Pozzi-Mucelli R. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: Diagnostic performance and confidence. Radiology 2004, 232:420-430.
12. Rappeport E.D., Loft A., Berthelsen A.K., von der Recke P., Larsen P.N., Mogensen A.M., Wettergren A., Rasmussen A., Hillingsoe J., Kirkegaard P., Thomsen C. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: A prospective study with intraoperative confirmation. Acta Radiol 2007, 48:369-378.
13. Schneider M., Broillet A., Bussat P., Giessinger N., Puginier J., Ventrone R., Yan F. Gray-scale liver enhancement in VX2 tumor-bearing rabbits using BR14, a new ultrasonographic contrast agent. Invest Radiol 1997, 32:410-417.
14. von Herbay A., Vogt C., Willers R., Haussinger D. Real-time imaging with the sonographic contrast agent SonoVue: Differentiation between benign and malignant hepatic lesions. JUltrasound Med 2004, 23:1557-1568.